Conditions & Recovery · NCI Cancer Currents Blog · May 2, 2025

FDA Approval Likely to Change Initial Treatment for Some People with Advanced Colorectal Cancer

FDA has approved the combination of the immunotherapy drugs ipilimumab (Yervoy) and nivolumab (Opdivo) for the initial treatment of people with advanced colorectal cancer whose tumors are classified as MSI-H or dMMR.

Originally published by NCI Cancer Currents Blog. We curate and add context; they did the reporting.

Read the full story at NCI Cancer Currents Blog ↗

Related learning

Biotech Firm Claims Some Credit for Groundbreaking Virus Research Biotech Firm Claims Some Credit for Groundbreaking Virus Research James P. Allison, Ph.D., bangs gong after completing proton therapy treatment Combination therapy helps plasmacytoid bladder cancer survivor